Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our experimental results further demonstrate that Co-fuse can identify known driver fusion genes (e.g., IGH-MYC, IGH-WHSC1) in MM, when compared to AML samples, indicating the potential of Co-fuse to aid the discovery of yet unknown driver fusion genes through cohort comparisons.
|
29882166 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified a 27-miRNA signature that included v-myc avian myelomatosis viral oncogene homolog (MYC) targets and enabled the differentiation of BL from DLBCL, a distinction comparable with the "gold standard" GEP-defined diagnosis.
|
25498913 |
2015 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MYC rearrangements are frequent in plasmablastic lymphomas, advanced plasma cell myelomas and a subgroup of diffuse large B-cell lymphomas, but their presence in ALK-positive large B-cell lymphomas is unknown.
|
23599149 |
2013 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MYC oncogene, known to drive myeloma progression, was downregulated in both in vitro and in vivo models when treated with [Au(d2pype)<sub>2</sub>]Cl.
|
31514052 |
2020 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we describe the mechanism of MYC activation in MM, the role of MYC in cancer progression, and the therapeutic options to targeting MYC.
|
29467490 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mice deficient for IL-18 were remarkably protected from Vk<sup>∗</sup>MYC MM progression in a CD8<sup>+</sup> T cell-dependent manner.
|
29551594 |
2018 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sporadic Burkitt's lymphoma and myelomas can arise due to translocation of the c-myc gene into the Ig heavy chain locus during class switch recombination.
|
16793349 |
2006 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Use of a dominant negative A1 construct, which prevents endogenous A1 from nucleus-to-cytoplasm transit, prevented the ability of IL-6 to enhance Myc internal ribosome entry site activity, Myc protein expression, and MM cell growth.
|
20974848 |
2011 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Loss of 1p and a rearrangement of MYC were first observed in a small population of plasma cells one year prior to the clinical diagnosis of multiple myeloma, but these subclones increased rapidly in size to become the major population suggesting that they were directly involved in the transformation process.
|
19454499 |
2009 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In cell lines derived from patients with multiple myeloma (MM) we have found an elevation in the amount of the c-myc protein which is not accompanied by an increase in the level of mRNA or a change in the half-life of the protein.
|
9308251 |
1997 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
|
24496825 |
2014 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma.
|
31221783 |
2019 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that the PT-LPDs are divisible into three distinct categories as follows: (1) plasmacytic hyperplasia: most commonly arise in the oropharynx or lymph nodes, are nearly always polyclonal, usually contain multiple EBV infection events or only a minor cell population infected by a single form of EBV, and lack oncogene and tumor suppressor gene alterations; (2) polymorphic B-cell hyperplasia and polymorphic B-cell lymphoma: may arise in lymph nodes or various extranodal sites, are nearly always monoclonal, usually contain a single form of EBV, and lack oncogene and tumor suppressor gene alterations; and (3) immunoblastic lymphoma or multiple myeloma: present with widely disseminated disease, are monoclonal, contain a single form of EBV, and contain alterations of one or more oncogene or tumor suppressor genes (N-ras gene codon 61 point mutation, p53 gene mutation, or c-myc gene rearrangement).
|
7812011 |
1995 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, CIP2A knockdown induced apoptosis and led to substantial reduction of c‑Myc protein levels in MM cell lines.
|
27484817 |
2016 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The other clone (myeloma (MM) clone) was characterized by a reciprocal translocation between the short arm of chromosome 8, band q24, a region known to contain the c-myc gene, and the long arm of chromosome 2, band p12, where the Ig kappa gene is located.
|
9406577 |
1998 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression profiling of MM cells revealed reversion of the oncogenic MYC-driven transcriptional program by CMLD010509, the most promising rocaglate.
|
28490664 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, the results suggest that targeting the MYC addiction in multiple myeloma is an efficient way of killing a majority of primary myeloma clones.
|
21941367 |
2012 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is suggested that the C-MYC gene may be activated by t(8;22)(q24;q11) and implicated in disease progression in multiple myeloma.
|
9666801 |
1998 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Using a combination of fluorescent in situ hybridization and comparative genomic hybridization arrays (aCGH), we have identified rearrangements of an MYC gene in 40 of 43 independent myeloma cell lines.
|
18647998 |
2008 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, C-MYC and cyclin D3 expression in CD56+ MM was similar to MGUS, whereas CD56- MM was similar to ExMM.
|
14531906 |
2003 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cancers like multiple myeloma (MM), which display elevated activity in key translation regulatory nodes, such as the PI3K/mammalian target of rapamycin and MYC-eukaryotic initiation factor (eIF) 4E pathways, are predicted to be particularly sensitive to therapeutic strategies that target this process.
|
25197055 |
2014 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It appears that increased MYC expression at the MGUS/MM transition usually is biallelic, but sometimes can be monoallelic if there is an MYC rearrangement.
|
24518206 |
2014 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The severe combined immune deficiency (SCID) mouse xenograft model revealed that compound 7594-0035 partially decreased the primary tumor growth of Roswell Park Memorial Institute (RPMI)-8226 cells <i>in vivo</i> The novel small molecular compound 7594-0035 described in the present study that targets c-Myc protein is likely to be a promising therapeutic agent for relapsed/refractory MM.
|
30068698 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glutaminase inhibition in multiple myeloma induces apoptosis <i>via</i> MYC degradation.
|
29156762 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using the Vk*MYC mouse model of multiple myeloma, we further demonstrate that exogenously administered CgA was cleaved in favor of the proangiogenic form and was associated with increased microvessel density.
|
26869462 |
2016 |